Carfilzomib
Carfilzomib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Multiple Myeloma、Plasma Cell Leukemia。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
7 项
已进入 III/IV 期
23 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Hackensack Meridian Health
- National Cancer Institute (NCI)
- Benjamin T Diamond, MD
- CellCentric Ltd.
- Wake Forest University Health Sciences
- Pfizer
- The First Affiliated Hospital of Soochow University
- Hoffmann-La Roche
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、Argentina、澳大利亚、比利时、Brazil、加拿大、Chile、Croatia、Czechia、丹麦、芬兰、法国
正在招募患者的 Carfilzomib 研究
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
II 期招募中美国NCT05896228Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma
III 期招募中美国NCT07772024Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
I 期招募中美国NCT03909412Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
I 期 / II 期招募中美国NCT04822337MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
III 期招募中美国Argentina澳大利亚比利时NCT06152575Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
IV 期招募中中国NCT06409702Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
III 期招募中美国澳大利亚Brazil加拿大NCT07555938A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
II 期招募中美国NCT04661137Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
不适用招募中中国NCT06682156Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
II 期招募中美国NCT06948084Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
I 期 / II 期招募中美国NCT07479979The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
II 期 / III 期招募中挪威NCT04513639KPD Consolidation After ASCT in NDMM Patients
II 期 / III 期招募中中国NCT06879379A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
III 期招募中美国澳大利亚BrazilChileNCT07222761A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
I 期招募中美国加拿大法国西班牙NCT05651932Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
II 期招募中美国NCT05789303Immunotherapy in Lymphoma
不适用招募中South KoreaNCT06796517A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
I 期 / II 期招募中美国澳大利亚Israel日本NCT06892522Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
I 期招募中美国NCT06249282Treatment of Antibody-Mediated Rejection (ABMR) With CarBel
I 期招募中美国NCT06918990Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
II 期招募中中国NCT06140966SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
I 期招募中美国NCT06622005Selinexor and Backbone Treatments of Multiple Myeloma Patients
I 期 / II 期招募中美国加拿大NCT02343042All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
II 期招募中中国NCT06158412
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。